In contrast, PI3K/AKT signalling pathway activities did not alter upon ERBB and ALK inhibition in the EML4-ALK-negative NSCLC cell line, A549 (Supplementary Fig. S7D, E). This evidence concerns the gene EGFR and non-small cell lung carcinoma.